SINGAPORE - Local genomic medicine company Lucence announced on Wednesday that it has received US$20 million in initial funding after it invented a non-invasive test for late-stage cancer detection.
Dr Tan, 45, told The Straits Times that Lucence conducts and processes the results of non-invasive tests on late-stage cancer patients using the company's patented sequencing test known as LiquidHallmark.It utilises a method known as liquid biopsy, where tests are conducted on a sample of blood to find cancer cells or pieces of DNA from tumours that may be circulating in the blood.
"There's a needle in haystack sort of problem, where there's a need to amplify and capture the signal of the mutant DNA," said Dr Tan.Invented by Dr Tan and his chief technology officer Dr Yukti Choudhury in 2018, it focuses on selected DNA fragments and multiplies them using a chemical process, amplifying the signal they give off."It's like a chemical photocopying machine," said Dr Tan.
In September this year, Lucence's Singapore laboratory became the first in South-east Asia to receive United States federal certification.
Sverige Senaste nytt, Sverige Rubriker
Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.
HDT Singapore Taxi second cab company equipped to respond to cardiac arrests and fire emergenciesSINGAPORE - HDT Singapore Taxi has become the second cab company to be equipped with automated external defibrillators (AED) that can be used in emergencies like heart attacks.. Read more at straitstimes.com.
Läs mer »